Long-term course of antiandrogen drugs — Competitive Intelligence Brief

Long-term course of antiandrogen drugs (Long-term course of antiandrogen drugs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiandrogen. Area: Oncology.

phase 3 Antiandrogen Androgen receptor Oncology Small molecule

Target snapshot

Long-term course of antiandrogen drugs (Long-term course of antiandrogen drugs) — The First Affiliated Hospital with Nanjing Medical University. Antiandrogen drugs block the effects of androgens (male hormones) by inhibiting androgen receptor signaling.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Long-term course of antiandrogen drugs TARGET	Long-term course of antiandrogen drugs	The First Affiliated Hospital with Nanjing Medical University	phase 3	Antiandrogen	Androgen receptor
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Nubeqa	darolutamide	Bayer	marketed		androgen receptor (AR)	2019-01-01
Erleada	apalutamide	Johnson & Johnson	marketed		Androgen receptor	2018-01-01
APALUTAMIDE	APALUTAMIDE		marketed		Androgen Receptor (AR)	2018-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiandrogen class)

1. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class